Suchen
Akoustis Technologies Ord Shs
AKTSZur Watchlist hinzufügen
21.880USD
-0.980-4.29%
Handelsschluss 09-18 16:00（ET）
1.21BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Akoustis Technologies Ord Shs Unternehmen
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shs Profil
BörsenkürzelAKTS
Name des UnternehmensAktis Oncology Inc
IPO-datumJan 09, 2026
CEORoden (Matthew)
Anzahl der mitarbeiter117
WertpapierartOrdinary Share
GeschäftsjahresendeJan 09
Addresse17 Drydock Avenue
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02210
Telefon13026587581
Websitehttps://www.aktisoncology.com/
BörsenkürzelAKTS
IPO-datumJan 09, 2026
CEORoden (Matthew)
Führungskräfte von Akoustis Technologies Ord Shs
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew (Matt) Roden, Ph.D.
Dr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Dr. Matthew (Matt) Roden, Ph.D.
Dr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Dr. Paul L. Feldman, Ph.D.
Dr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board
Chairman of the Board
--
-100.00%
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D., Ph.D.
Mr. Akos Czibere, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
Mr. Lloyd M. Segal
Mr. Lloyd M. Segal
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Matthew (Matt) Roden, Ph.D.
Dr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Dr. Matthew (Matt) Roden, Ph.D.
Dr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
91.99K
-0.01%
Dr. Paul L. Feldman, Ph.D.
Dr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board
Chairman of the Board
--
-100.00%
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Akoustis Technologies Ord Shs?
Die fünf größten Anteilseigner von Akoustis Technologies Ord Shs sind: Dr. Matthew (Matt) Roden, Ph.D.
Wie viele Institutionen halten Anteile an Akoustis Technologies Ord Shs (AKTS)?
Mit Stand vom 2026Q1 halten 195 Institutionen Anteile an Akoustis Technologies Ord Shs, mit einem Gesamtmarktwert von etwa 27.52M, was 51.47% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1127277.00 gestiegen.